HC Wainwright Downgrades TRAW to Hold

On June 18, 2026, HC Wainwright downgraded TRAW's stock to a hold rating, setting a new price target of $1.00. This update comes as TRAW shares are trading at $0.80, suggesting a cautious outlook by the analyst.

Other Institutional Activity in TRAW

Adage Capital Partners GP, L.L.C. maintained its position in TRAW with 730,000 shares valued at about $1.34 million. Ikarian Capital, LLC also held steady with 678,142 shares worth approximately $1.24 million. OrbiMed Advisors LLC kept 605,531 shares, valued at around $1.11 million. Squadron Capital Management LLC, however, reduced its stake by 201,826 shares, now holding 511,714 shares valued at roughly $936,437. Meanwhile, Dauntless Investment Group, LLC entered a new position, purchasing 416,998 shares worth $763,106.

Insider Buying and Selling at Traws Pharma, Inc.

On April 16, 2026, OrbiMed Advisors LLC made several purchases of TRAW shares, including 597,729 shares at an average price of $1.67. Additionally, Parker Charles Nolan, TRAW's Chief Financial Officer, bought 104,544 shares on March 8, 2026.

Analysts Set New Price Targets

On June 18, 2026, HC Wainwright & Co. downgraded TRAW to a hold rating with a price target of $1.00. Previously, on May 20, 2026, the same firm reiterated a buy rating with a target of $8.00. The consensus among analysts suggests a mixed outlook for TRAW.

About TRAW

TRAW operates in a sector and industry that was not specified in the available data. The company's headquarters, CEO, and employee numbers were also not provided in the current dataset.

Bottom Line

The recent downgrade by HC Wainwright reflects cautious sentiment around TRAW, with the stock trading below the new price target. Institutional activity shows mixed strategies among investors, with some maintaining or increasing their positions and others reducing their stakes. Investors should note that analyst ratings and institutional moves are backward-looking and may not reflect current market dynamics.